• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Hefty Action in a Pair of Biotechs

I've got my eye on these, though I wouldn't act until the market decides on a direction.
By KATE STALTER Jun 27, 2012 | 09:30 AM EDT
Stocks quotes in this article: GEVA, SPPI

Some of the Nasdaq's biggest upside movers Monday in heavier-than-normal trading volume hailed from the biotech area of healthcare.

As I've often written here, it's worth tracking such stocks in a poor market, as they could be setting up for more price gains when a new uptrend is defined. Generally I run scans for companies that are showing double-digit earnings growth, driven by rising revenue.

But, with many of the biotech names, it's possible to unearth strong technical contenders from the ranks of companies that are yet to turn a profit. That's because, in this industry driven by research and development, it's very typical for companies to be dependent on additional rounds of capital in order to stay in business. That tends to apply until one of their products is a hit, or -- as is often the case -- the company is acquired.

One such unprofitable name with a strong chart is Synageva BioPharma (GEVA), which specializes in treatments for viral conditions. In November, the company completed its $35 million acquisition of Trimeris, maker of anti-HIV drug Fuzeon. 

After a 137% rally between Nov. 4 and Jan. 31, the stock retreated into a consolidation. Similar to the rest of the market, the stock has struggled of late. It attempted a breakout in late April, around the time the major indices went into a failed rally attempt. Most stocks trade in tandem with the broader market -- so, unsurprisingly, Synageva fell back into a base.

The stock's consolidations have been constructive: The latest pullback formed a double-bottom pattern, which is often a bullish precursor to further price gains. The stock cleared that base in heavy volume on Monday, but retreated slightly in Tuesday trade. Monday's 5.8% price move, to a new closing high of $40.74, followed Cannacord Adams' initiation of the stock with a rating of Buy.

I don't make macro predictions about what may or may not affect markets, but it's fairly obvious that there are plenty of developments in the coming days with potential to move the market one way or another.

With the European Union summit looming in the coming days, along with a Supreme Court decision on healthcare, the next several sessions have potential to show reactive action. In any event, news and economic developments have proven to be catalysts that send stocks into whipsaw action. Given that, I'm staying on the sidelines in the current market environment until a trend -- whether up or down -- is more clearly defined.

Another big mover from Monday, and one that's still working on a constructive base, is another biotech: Spectrum Pharmaceuticals (SPPI). This company develops products for oncology and urology treatments. The stock began consolidating January, and it has been attempting to etch the right side of that downturn since April. 

This is a stock that historically has rallied to further highs after clearing areas of consolidation. As of now, a possible entry point could materialize as the stock surpasses resistance at its prior high of $16. However, an opportunity could present itself at a lower price -- for example, if the stock forms a handle area before it rallies as high as $16.

While this company has been in rally mode lately, buyers could get caught in a bout of selling that pulls the stock below its purchase price. While there seem to be many tempting opportunities right now, I'm content to preserve capital and wait for a clear trend to emerge.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stalter had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login